Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Umecrine Cognition AB via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Språk
Typ
Språk
Typ
2026-04-30 10:00:00
Notice to attend the Annual Shareholders’ Meeting in Umecrine Cognition AB, on May 26, 2026, at 08:30 (am)
The shareholders in Umecrine Cognition AB, reg. no. 556698- 3655, are hereby given notice to attend the annual general shareholders’ meeting at 8:30 a.m. on Thursday 26 May 2026 at the company’s offices at Nanna Svartz väg 2 in Solna, Sweden. Registration for the meeting commences at 08:10 (CEST). The complete notice can be found on the company’s website (https://www.umecrinecognition.com/e...
2021-10-04 08:00:00
Umecrine Cognition CEO Magnus Doverskog to present at Vator Securities Healthcare Innovation Summit
STOCKHOLM. Umecrine Cognition announced today that CEO Magnus Doverskog will present at Healthcare Innovation Summit on October 7, 2021. Vator Securities Healthcare Innovation Summit is a digital investor event including some of the most innovative and fastest growing companies in the healthcare sector. The event will include focused insights into these healthcare companies, including fire side ch...
2021-04-21 08:00:00
Umecrine Cognition announces publication in the Journal of Hepatology of the results of a pilot study of golexanolone in patients with hepatic encephalopathy
STOCKHOLM. Umecrine Cognition AB today announced that the Journal of Hepatology has published safety, pharmacokinetic, and preliminary efficacy results from the pilot Phase 2a study of golexanolone in patients with cirrhosis and covert hepatic encephalopathy (HE). The clinical trial results demonstrate that the company’s candidate drug, golexanolone, improved neuropsychiatric performance at dose...
2020-09-02 08:00:00
Umecrine Cognition to present clinical Phase 2a results at AASLD International Liver Meeting
STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company whose novel orally-active GABAA receptor modulating steroid antagonist, golexanolone, is in clinical development for hepatic encephalopathy (HE), will present clinical results from its Phase 2a study at The Liver Meeting Digital ExperienceTM 2020, the premier Annual Meeting of the American Associa...
2020-05-08 08:00:00
Umecrine Cognition announces positive additional endpoint data from a phase 2a study with golexanolone in hepatic encephalopathy
STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company focused on developing a new class of neurosteroid based drugs for CNS disorders, today announced positive data based on prespecified analyses of additional endpoint data from a phase 2a study of the safety, pharmacokinetics and exploratory efficacy of golexanolone (formerly GR3027) in patients wit...
2020-04-03 08:00:00
Umecrine Cognition announces top-line results from its phase 2a study with golexanolone in hepatic encephalopathy
STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company focused on developing a new class of neurosteroid based drugs for CNS disorders, today announced results based on initial review of the topline data set from a phase 2a study of the safety, pharmacokinetics and exploratory efficacy of golexanolone (formerly GR3027) in hepatic encephalopathy
2019-12-20 08:00:00
Umecrine Cognition announces a Notice of Allowance from USPTO for a patent protecting a pharmaceutical formulation of its proprietary lead compound golexanolone
STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (NASDAQ Stockholm: KDEV) portfolio company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent protecting a pharmaceutical formulation of its lead candidate drug golexanolone, currently in clinical Phase 2a development for hepatic encephalopathy. Upon issuance, the grant...
2019-12-13 08:00:00
Umecrine Cognition announces completion of enrollment in clinical Phase 2a study with golexanolone in patients with liver cirrhosis and hepatic encephalopathy
STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, today announced that enrollment has been completed in its Phase 2a study designed to assess the safety, pharmacokinetics and potential benefit of golexanolone, a novel GABAA receptor modulating steroid antagonists, in development for treatment of Hepatic Encephalopathy (HE) in patients with liver...
2019-02-18 08:00:00
Umecrine Cognition announces first patient included in part D in clinical Phase 2a study with GR3027 in patients with liver cirrhosis and hepatic encephalopathy
STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, today announced enrollment of the first patient in the final part of a Phase 2a study designed to assess the safety, pharmacokinetics and potential benefit of GR3027, a novel GABAA receptor modulating steroid antagonists (GAMSA), under development for treatment of Hepatic Encephalopathy (HE)
2019-01-29 08:00:00
Umecrine Cognition announces results from a Phase 2a study of GR3027 in patients with idiopathic hypersomnia
STOCKHOLM/UMEÅ. Umecrine Cognition today reports results from a phase 2a study of GR3027 – a first-in-class drug candidate being developed as a potential new treatment for a range of CNS-related disorders. The primary study objectives were met in regard to safety and pharmacokinetics. The study also showed preliminary evidence of clinical efficacy in a subset of patients, but the data needs to ...
2018-12-12 08:00:00
Umecrine Cognition granted a European patent protecting its lead candidate drug GR3027
STOCKHOLM. Umecrine Cognition AB today announces that the European Patent Office (EPO) has granted a patent covering its lead candidate drug GR3027 for the medical use in hepatic encephalopathy (HE). The granted patent will expire in 2035
2018-12-03 08:00:00
Umecrine Cognition appoints Dr. Eva Arlander as Chief Development Officer
STOCKHOLM/UMEÅ. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company in clinical development with a novel GABAA receptor modulator for the treatment of CNS-related disorders, today announces that Dr. Eva Arlander has been appointed as Chief Development Officer
2018-03-02 08:00:00
Umecrine Cognition announces on-line publication of Clinical trial results perteining to GR3027 safety, pharmacokinetics and CNS target engagement
STOCKHOLM. Umecrine Cognition AB is pleased to announce the publication in Psychopharmacology of clinical trial results which demonstrate that the company’s candidate drug, GR3027, reverses the brain-inhibitory effects of allopregnanolone at doses which are well tolerated and exhibit excellent pharmacokinetics
2017-11-20 08:00:00
Umecrine Cognition announces first patient included in clinical Phase 2a study in patients with sleep disorder
STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, today announces the inclusion of the first patient in a clinical Phase 2a study with the lead compound GR3027 in patients with idiopathic hypersomnia
2017-10-04 08:00:00
Umecrine Cognition raises SEK 20 million to treat unmet needs in sleep disorder
STOCKHOLM. Umecrine Cognition AB today announces the closing of a financing round raising SEK 20 million (US$2.5 million). Financing will support an exploratory clinical phase IIa trial with the lead compound GR3027 in patients with idiopathic hypersomnia. Current investors Fort Knox Förvaring AB, Stiftelsen Norrlandsfonden, Torbjörn Bäckström, and Karolinska Development (Nasdaq Stockholm: KDE...
2017-09-13 08:00:00
Umecrine Cognition announces positive data from its Phase 1b study of GR3027 - a potential new treatment of hepatic encephalopathy
STOCKHOLM/UMEÅ. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company today announced positive results from its Phase 1b multiple ascending dose trial in healthy male subjects with GR3027, a novel orally active GABAA receptor modulating steroid antagonist, in development for treatment of hepatic encephalopathy (HE) in patients with liver cirrhosis
2017-09-05 08:00:00
Umecrine Cognition appoints Dr. Thomas P. Blackburn to its board of directors
STOCKHOLM/UMEÅ. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company in clinical development with a novel GABAA receptor modulator for the treatment of hepatic encephalopathy (HE) in patients with liver disease, today announces that Dr. Thomas P. Blackburn has been appointed as a new member of its Board of Directors and Senior Development Adviser
2017-04-21 08:00:00
Umecrine Cognition to present at the EASL International Liver Congress 2017
STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company whose novel orally-active GABAA receptor modulating steroid, GR3027, is in clinical development for hepatic encephalopathy (HE), will present clinical results from its Phase 1 study at The International Liver CongressTM 2017, the annual meeting of the European Association for the Study of the Live...
2017-03-17 08:00:00
Umecrine Cognition announces first patient included in Clinical Phase 1b/2a study with GR3027, a novel drug candidate for Hepatic Encephalopathy
STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company in clinical development, today announces the inclusion of the first patient in a clinical Phase 1b/2a study of GR3027, which is in development as a potential new treatment for Hepatic Encephalopathy
2016-11-22 08:00:00
Umecrine Cognition raises SEK 45 million to advance GR3027, a novel drug candidate for hepatic encephalopathy
STOCKHOLM. Umecrine Cognition AB today announces the closing of a financing round raising SEK 45 million (US$4.9 million) in accordance with the company’s strategy to develop and commercialize its lead compound GR3027 for the treatment of patients with liver cirrhosis and hepatic encephalopathy. Current investors Fort Knox Förvaring AB, Partnerinvest Övre Norrland AB, Norrlandsfonden and Karol...
2016-11-03 08:00:00
Positive Phase 1 top line data with GR3027 demonstrate safety, tolerability, and CNS target engagement
STOCKHOLM/UMEÅ. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company today announced positive top-line results from its Phase 1 first in human clinical trial with GR3027, a novel orally active GABAA receptor modulating steroid antagonist, in development for treatment of hepatic encephalopathy (HE) in patients with liver cirrhosis
2016-07-05 08:00:00
Umecrine Cognition appoints Dr. Bruce Scharschmidt to its board of directors
STOCKHOLM/UMEÅ. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company in clinical development with a novel treatment for hepatic encephalopathy (HE) in patients with liver disease, today announces that Dr. Bruce Scharschmidt has been appointed as a new member of its board of directors and Senior Development Adviser
2016-03-10 08:00:00
Umecrine Cognition raises new funds to support clinical development of novel drug candidate GR3027 for Hepatic Encephalopathy - Phase I clinical trial initiated
STOCKHOLM/UMEÅ – Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company developing a novel treatment for hepatic encephalopathy (HE) in patients with liver disease, today announces it has completed a private financing round that will support the clinical development of its lead drug candidate for HE in liver disease patients. New investors, Fort Knox Förvari...